Potential conflict of interest: J.G. has consulted for Gilead; A.S.P. has received research grants from Novartis and Roche and has consulted for Merck, Gilead, Achillion, Bristol-Myers Squibb, Progenics, and Santaris Pharmaceuticals; S.K. was employed by Novartis when this work was done (currently at the Bill and Melinda Gates Foundation); and J.Y., M.L., B.L., and N.V.N. are Novartis employees.
Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients
Article first published online: 1 APR 2014
© 2014 by the American Association for the Study of Liver Diseases. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
Volume 59, Issue 5, pages 1706–1714, May 2014
How to Cite
Guedj, J., Yu, J., Levi, M., Li, B., Kern, S., Naoumov, N. V. and Perelson, A. S. (2014), Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients. Hepatology, 59: 1706–1714. doi: 10.1002/hep.26989
- Issue published online: 23 APR 2014
- Article first published online: 1 APR 2014
- Accepted manuscript online: 23 DEC 2013 03:36AM EST
- Manuscript Accepted: 19 DEC 2013
- Manuscript Received: 13 JUL 2013
Options for accessing this content:
- If you would like institutional access to this content, please recommend the title to your librarian.
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- New Users: Please register, then proceed to purchase the article.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!
Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.